(Press-News.org) In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people living with amyotrophic lateral sclerosis (ALS), with exploratory findings suggesting target engagement and potential clinical benefits. Results of the PARADIGM study, led by researchers at Mass General Brigham Neuroscience Institute and Barrow Neurological Institute, were published in JAMA Neurology.
ALS is a progressive neurodegenerative and typically fatal disease marked by the loss of motor neurons and the gradual increase in muscle weakness. PrimeC, a combination of celecoxib and ciprofloxacin, is designed to target the neuroinflammation, excess iron accumulation, and abnormal microRNA activity that occurs in ALS.
The multicenter trial randomized 68 participants 2:1 to receive PrimeC or placebo for six months, followed by a 12-month open-label extension in which all received PrimeC. While drug-related adverse events were more common with PrimeC (20.0% vs 4.3%), most of the adverse events were mild to moderate and temporary.
Although the study was not powered to assess efficacy, participants in the PrimeC arm had better functional outcomes, especially for speech and swallowing, as measured by an ALS Functional Rating Scale Revised (ALSFRS-R) score. At 6 months, participants taking PrimeC scored 2.23 points higher than those taking placebo. By 18 months, participants originally assigned to PrimeC scored 7.92 points higher, on average, than their counterparts. Early, continuous treatment was also associated with a 64% reduced risk of ALS-related complications, including hospitalization, respiratory failure or death.
Exploratory biomarker analyses showed those initially assigned to PrimeC had lower levels of ferritin, a key protein involved in storing iron in the body. Treatment was also associated with lower levels of microRNA molecules that have been linked to ALS. There were no treatment related changes in blood levesl of neurofilament light change between the two groups.
“The improved functional and biomarker signals we observed support a phase 3 study to evaluate PrimeC’s effectiveness and safety in a larger population,” said first author Merit Cudkowicz, MD, MSc, Executive Director of Mass General Brigham Neuroscience Institute and Director of the Sean M. Healey & AMG Center for ALS. “The importance of following up on potential therapies that can slow the course of ALS is extraordinarily high for patients and families. We are determined to accelerate the development of therapies for people living with ALS.”
“What stands out about the PARADIGM study is that multiple clinical endpoints suggest the same level of clinical benefit and that multiple biomarkers are consistent with clinical endpoints,” said Jeremy M. Shefner, MD, PhD, professor of Neurology at Barrow Neurological Institute and corresponding author of the publication. “Together, these findings provide a strong scientific foundation for advancing PrimeC into a Phase 3 trial designed to validate its impact for patients.”
Authorship: In addition to Cudkowicz and Shefner, co-authors include Vivian E. Drory, Adriano Chio, Christian Lunetta, Christen Shoesmith, Ruben P.A van Eijk, Shiran Salomon-Zimri, Diana Shtossel, Nitai Kerem, Guy Shapira, Noam Shomron, Niva Russek-Blum, Ferenc Tracik, and Jeffrey Rosenfeld.
Disclosures: Cudkowicz reported research funding from the NIH and ALSFAC; consultant fees from Aclipse, Immunity Pharm, Inflectis, Novartis, Ono, Roche, Denali, Als Pharma, Transposon, Quralis, Regeneron, AB Sciences, Locust Walk, Coya, Pasithea, Otsuka, Cytokinetics, Takeda, Biogen, Eledon, Vector Y and NeuroSense; and serving on the Board of Directors for Praxis. Dr Drory reported personal consulting fees from Argenx, Medison Pharma and Takeda; honoraria from Medison Pharma and Neopharm Israel; and meeting registration support from NeuroSense and Medison Pharma. Additional author disclosures can be found in the paper.
Funding: PARADIGM was conducted and funded by NeuroSense Therapeutics. The sponsor played a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and editorial services for and decision to submit the manuscript for publication.
Paper cited: Cudkowicz M et al. “Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: Results from the PARADIGM Phase 2b” JAMA Neurology DOI: 10.1001/jamaneurol.2026.0230
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
About Barrow Neurological Institute
Barrow Neurological Institute, at Dignity Health St. Joseph's Hospital and Medical Center in Phoenix, is an international leader in treatment, research and education relating to brain and spinal diseases, conditions, and injuries. The Institute is one of the busiest centers for neurology and neurosurgery in the United States. Each year, more than 73,000 patients are treated at Barrow with more than 6,000 neurosurgeries performed at the Institute. Because of its high volume, Barrow clinicians are familiar with the rarest and most challenging neurological conditions and are often sought by patients from around the world for life-saving medical care. About Barrow Neurological Institute. To learn more about Barrow, please follow us on Facebook, Instagram, LinkedIn and X.
END
About The Study: This randomized clinical trial found that continuing glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) agonist in the preprocedural period increased clinically significant residual gastric volume (RGV) but did not increase the risk of other adverse events. Clear liquids the day prior to the procedure may mitigate the risk of clinically significant RGV regardless of GLP-1/GIP use.
Corresponding Author: To contact the corresponding author, Tilak Shah, MD, MHS, email shaht3@ccf.org.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2026.0027)
Editor’s ...
In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder (OUD) during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue (sublingual), one of the standard methods of treatment. Additionally, serious adverse events were less common in those receiving extended-release treatment. The findings, which support the use of this formulation of buprenorphine for treating OUD during ...
BALTIMORE, MD, March 14, 2026, Dr. Thomas Hartung, Director of the Center for Alternatives to Animal Testing (CAAT) at the Johns Hopkins Bloomberg School of Public Health, has endorsed the public launch of ToxIndex, an agentic AI platform developed by Insilica Inc. that produces comprehensive, source-traceable toxicological risk assessments in just a few hours.
The launch of ToxIndex meets a critical need in chemical and drug safety, as well as in exposomics, a field of study that considers the effects of environmental exposures on human health and serves as a complement and counterpart to ...
Type 2 diabetes (T2D) and obesity are metabolic conditions with many causes, including overlapping and distinct genetic features. A polygenic risk score (PRS) can capture multiple genetic risk factors to provide an estimate for whether a person may develop a complex medical condition and how they might fare long-term. By integrating genetic findings from several of the world’s largest biobanks, investigators from Mass General Brigham built metabolic PRSs for predicting obesity and T2D, which outperformed existing ...
Dielectric ceramic capacitors are critical components in modern electronics and pulsed power systems, prized for their ultra-fast charge–discharge capabilities and high-power density. However, their real-world application has been constrained by modest recoverable energy storage density (Wrec) and energy efficiency (η), especially under extreme operating conditions.
Now, a research team led by Professor Changzheng Hu from the College of Materials Science and Engineering at Guilin University of Technology has developed a new class of lead-free relaxor ferroelectric ceramics that overcome these limitations. By integrating high-entropy design with bandgap engineering, ...
Dielectric ceramic capacitors are essential core components for electronics, smart grids and new energy vehicles, prized for their high power density. As electronic devices move toward miniaturization and intelligence, the demand for lead-free dielectric ceramics with ultrahigh recoverable energy storage density (Wrec) and high efficiency (η) is becoming increasingly urgent. Relaxor ferroelectrics (RFE) suffer from relatively large remnant polarization, while superparaelectric relaxor ferroelectrics (SPE-RFE) see ...
Febrile neutropenia (FN) is a serious chemotherapy complication defined by fever (≥38.3°C) and low neutrophil count (<0.5×10⁹/L). It affects 7–8 per 1,000 cancer patients, with 9.5% mortality. FN often leads to chemotherapy delays, compromising treatment efficacy. Current standard care—antibiotics and granulocyte colony-stimulating factor (G-CSF)—faces limitations including antibiotic resistance, G-CSF side effects (bone pain, vasculitis), and refractory cases. Traditional Chinese ...
Thermal barrier coatings are indispensable shields that protect the hot-end components of gas turbines and aircraft engines from extreme temperatures. Current industry-standard YSZ coatings face several critical limitations: an unstoppable phase transition that restricts operating temperatures below 1200 °C, dramatically rising thermal conductivity due to thermal radiation above 900 °C, severe corrosion by CaO–MgO–Al2O3–SiO2 (CMAS) melts, and vulnerability to moisture degradation. These combined deficiencies have driven urgent demand for next-generation TBC materials capable of sustained service at 1200–1500 °C.
High-entropy ...
(Toronto, March 16, 2026) JMIR Publications is proud to announce the appointment of Dr. Sara Simblett as the new editor in chief of JMIR Neurotechnology.
Dr. Sara Simblett is a clinical academic whose work focuses on digital health innovation, patient engagement, and the integration of technology into neuropsychology and broader mental health services. Her research is translational, combining clinical psychology, implementation science, and data-driven methodologies, such as ecological momentary assessment and the use of mobile technology, to evaluate and scale digital interventions that improve ...
SAN ANTONIO — March 16, 2026 — Southwest Research Institute (SwRI) has received a contract from the U.S Air Force Academy to characterize inspection methods for bolt holes in aging aircraft to inspect through bushings without removing them. Assessing bolt hole condition inspection supports wider efforts that inform repair decisions and ensure aircraft safety.
For decades, SwRI has supported the U.S. Air Force’s Aircraft Structural Integrity Program (ASIP) and the U.S. Air Force Academy Center for Aircraft Structural Life Extension ...
